BG105253A - Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate - Google Patents

Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate

Info

Publication number: BG105253A
Authority: BG; Bulgaria
Prior art keywords: propylcarbamate; phosphonooxy; aminophenyl; furanyl; tetrahydro
Prior art date: 1998-07-18

Application number

BG105253A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ian ARMITAGE

Andrew Searle

Hardev Singh

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-18

Filing date

2001-02-14

Publication date

2001-12-29

2001-02-14 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-12-29 Publication of BG105253A publication Critical patent/BG105253A/xx

Links

CDRQNDUZTKTSBS-NHALQGLQSA-L calcium;n-[(2s,3r,4s)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-cyclohex-2-en-1-yl-4-(furan-2-yl)-3-phosphonooxybutan-2-yl]carbamate Chemical compound [Ca+2].C([C@@H]([C@@H](OP(O)(O)=O)[C@H](N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C=1OC=CC=1)NC([O-])=O)C1CCCC=C1.C([C@@H]([C@@H](OP(O)(O)=O)[C@H](N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C=1OC=CC=1)NC([O-])=O)C1CCCC=C1 CDRQNDUZTKTSBS-NHALQGLQSA-L 0.000 title 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
229910052791 calcium Inorganic materials 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG105253A 1998-07-18 2001-02-14 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate BG105253A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9815567.4A GB9815567D0 (en)	1998-07-18	1998-07-18	Antiviral compound
PCT/EP1999/004991 WO2000004033A1 (en)	1998-07-18	1999-07-15	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Publications (1)

Publication Number	Publication Date
BG105253A true BG105253A (en)	2001-12-29

Family

ID=10835689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105253A BG105253A (en)	1998-07-18	2001-02-14	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate

Country Status (48)

Country	Link
US (3)	US6514953B1 (de)
EP (2)	EP1098898B1 (de)
JP (1)	JP3437553B2 (de)
KR (1)	KR100694721B1 (de)
CN (1)	CN1188422C (de)
AP (1)	AP2001002039A0 (de)
AR (1)	AR019388A1 (de)
AT (1)	ATE229964T1 (de)
AU (1)	AU766056B2 (de)
BG (1)	BG105253A (de)
BR (1)	BRPI9912156B8 (de)
CA (1)	CA2337857C (de)
CO (1)	CO5090836A1 (de)
CZ (1)	CZ300447B6 (de)
DE (1)	DE69904600T2 (de)
DK (1)	DK1098898T3 (de)
DZ (1)	DZ2845A1 (de)
EA (1)	EA003191B1 (de)
EE (1)	EE200100038A (de)
ES (1)	ES2189450T3 (de)
GB (1)	GB9815567D0 (de)
GC (1)	GC0000105A (de)
GE (1)	GEP20033030B (de)
GT (1)	GT199900111A (de)
HK (1)	HK1034261A1 (de)
HR (1)	HRP20010046A2 (de)
HU (1)	HU229700B1 (de)
ID (1)	ID28070A (de)
IL (1)	IL140824A (de)
IS (1)	IS5808A (de)
JO (1)	JO2114B1 (de)
MA (1)	MA26660A1 (de)
MY (1)	MY122323A (de)
NO (1)	NO329676B1 (de)
NZ (1)	NZ509291A (de)
OA (1)	OA11706A (de)
PA (1)	PA8477801A1 (de)
PE (1)	PE20000869A1 (de)
PL (1)	PL195736B1 (de)
PT (1)	PT1098898E (de)
SK (1)	SK285311B6 (de)
SV (1)	SV1999000096A (de)
TN (1)	TNSN99145A1 (de)
TR (1)	TR200100111T2 (de)
TW (1)	TWI245770B (de)
WO (1)	WO2000004033A1 (de)
YU (1)	YU3401A (de)
ZA (1)	ZA200100417B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9914821D0 (en) *	1999-06-24	1999-08-25	Glaxo Group Ltd	Compounds
DK1222192T3 (da) *	1999-10-06	2008-10-20	Tibotec Pharm Ltd	Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor
EP1226138B1 (de) *	1999-10-08	2004-12-29	Affinium Pharmaceuticals, Inc.	Fab i inhibitoren
US7049310B2 (en) *	2001-04-06	2006-05-23	Affinium Pharmaceuticals, Inc.	Fab I inhibitors
JP2005523922A (ja)	2002-04-26	2005-08-11	ギリアードサイエンシーズ，インコーポレイテッド	非ヌクレオシド逆転写酵素阻害剤
DK1575951T3 (da) *	2002-12-06	2014-09-15	Debiopharm Int Sa	Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (en)	2003-03-17	2013-08-06	Affinium Pharmaceuticals, Inc.	Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
ATE490788T1 (de)	2003-04-25	2010-12-15	Gilead Sciences Inc	Antivirale phosphonate analoge
US7470724B2 (en)	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en)	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
WO2005002626A2 (en)	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
WO2004096287A2 (en)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
CA2522845A1 (en)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
US7407965B2 (en)	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
US7452901B2 (en)	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
WO2004096285A2 (en)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Anti-infective phosphonate conjugates
PT1670448E (pt) *	2003-09-30	2008-02-11	Tibotec Pharm Ltd	Sulfonamidas inibidoras de hcv
EP1680512A1 (de)	2003-10-24	2006-07-19	Gilead Sciences, Inc.	Verfahren und zusammensetzungen zur identifizierung therapeutischer verbindungen
WO2005044279A1 (en)	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Purine nucleoside phosphonate conjugates
WO2005044308A1 (en)	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Phosphonate analogs of antimetabolites
KR20060127906A (ko)	2003-12-22	2006-12-13	길리애드 사이언시즈, 인코포레이티드	4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
DK1828167T3 (da) *	2004-06-04	2014-10-20	Debiopharm Int Sa	Acrylamidderivater som antibiotiske midler
EP1778251B1 (de)	2004-07-27	2011-04-13	Gilead Sciences, Inc.	Nukleosid phosphonat konjugate als anti hiv mittel
ES2341120T3 (es)	2004-11-26	2010-06-15	Ucl Business Plc	Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
JP2009518399A (ja) *	2005-12-05	2009-05-07	アフィニウムファーマシューティカルズ，インク．	Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
EP2687533B1 (de)	2006-07-20	2017-07-19	Debiopharm International SA	Acrylamidderivate als FAB-I-Hemmer
US8263613B2 (en) *	2007-02-16	2012-09-11	Affinium Pharmaceuticals, Inc.	Salts, prodrugs and polymorphs of fab I inhibitors
CN102816111B (zh)	2007-03-12	2014-08-06	尼克塔治疗公司	低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) *	2008-03-12	2015-08-04	Nektar Therapeutics	Reagents
ES2393962T3 (es)	2008-07-08	2013-01-03	Gilead Sciences, Inc.	Sales de compuestos inhibidores del VIH.
CA2998344C (en)	2009-04-03	2020-06-02	Ocera Therapeutics, Inc.	L-ornithine phenyl acetate and methods of making thereof
EP2432788A1 (de) *	2009-05-20	2012-03-28	Ranbaxy Laboratories Limited	Amorphes fosamprenavircalcium
MX2011013129A (es)	2009-06-08	2012-03-14	Ucl Business Plc	Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
WO2010144869A2 (en)	2009-06-12	2010-12-16	Nektar Therapeutics	Protease inhibitors
EP2448949A1 (de) *	2009-06-30	2012-05-09	Ranbaxy Laboratories Limited	Kristalline form von fosamprenavir-calcium
EP2477996A1 (de)	2009-09-16	2012-07-25	Ranbaxy Laboratories Limited	Verfahren zur herstellung von fosamprenavircalcium
WO2011085130A1 (en) *	2010-01-07	2011-07-14	Pliva Hrvatska D.O.O.	Solid state forms of fosamprenavir calcium salt and process for preparation thereof
DK3127542T3 (en)	2010-01-27	2018-11-12	Viiv Healthcare Co	ANTIVIRAL THERAPY
US20110224443A1 (en) *	2010-03-15	2011-09-15	Venkata Naga Brahmeshwara Rao Mandava	Preparation of fosamprenavir calcium
WO2011114212A1 (en)	2010-03-19	2011-09-22	Lupin Limited	Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) *	2010-06-18	2011-12-22	Matrix Laboratories Ltd	Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
US8877947B2 (en)	2010-09-10	2014-11-04	Lupin Limited	Process for preparation of substantially pure fosamprenavir calcium and its intermediates
WO2012048043A1 (en)	2010-10-06	2012-04-12	Ocera Therapeutics, Inc.	Methods of making l-ornithine phenyl acetate
CN102453054B (zh) *	2010-10-29	2015-06-10	浙江九洲药业股份有限公司	一种福沙那韦衍生物的制备方法及相关中间体
CN102453053B (zh) *	2010-10-29	2014-11-26	浙江九洲药业股份有限公司	一种福沙那韦钙晶体及其制备方法
WO2012085625A1 (en)	2010-12-21	2012-06-28	Lupin Limited	Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en)	2011-02-10	2015-03-31	Mylan Laboratories Ltd.	Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (en)	2011-07-20	2013-01-24	Ranbaxy Laboratories Limited	Process for the preparation of sulfonamides useful as retroviral protease inhibitors
WO2013105118A1 (en)	2012-01-10	2013-07-18	Council Of Scientific & Industrial Research	A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
EP2861608B8 (de)	2012-06-19	2019-06-19	Debiopharm International SA	Prodrug-derivate von (e)-n-methyl-n-((3-methylbenzofuran-2-yl) methyl)-3- (7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
AU2015353703B2 (en)	2014-11-24	2021-04-01	Ucl Business Plc	Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
JP6990170B2 (ja)	2015-08-18	2022-01-12	オセラセラピューティクス，インコーポレイテッド	Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
MY189221A (en)	2016-02-26	2022-01-31	Debiopharm Int Sa	Medicament for treatment of diabetic foot infections
JP7126520B2 (ja)	2017-05-11	2022-08-26	オセラセラピューティクス，インコーポレイテッド	Ｌ－オルニチンフェニルアセテートを製造する方法
PT3661937T (pt)	2017-08-01	2021-09-24	Gilead Sciences Inc	Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2698826A (en) *	1951-02-13	1955-01-04	Merco Centrifugal Co	Alcohol manufacturing process
US3437267A (en) *	1966-03-24	1969-04-08	Alfa Laval Ab	Centrifuge
JPH0244315B2 (ja) *	1982-06-14	1990-10-03	Microbial Chem Res Found	Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) *	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) *	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) *	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
SK9672000A3 (en) *	1997-12-24	2001-04-09	Vertex Pharmaceuticals Inc Ver	Prodrugs of aspartyl protease inhibitors
AU2010299A (en) *	1997-12-24	1999-07-19	Vertex Pharmaceuticals Incorporated	Prodrugs os aspartyl protease inhibitors
GB9812189D0 (en) *	1998-06-05	1998-08-05	Glaxo Group Ltd	Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) *	1998-09-28	2000-04-17	Glaxo Group Limited	Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
WO2000025784A1 (en) *	1998-11-04	2000-05-11	Pharmacia & Upjohn Company	Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) *	1998-12-23	2000-11-15	Vertex Pharmaceuticals Incorporated	Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) *	1999-06-24	1999-08-25	Glaxo Group Ltd	Compounds
ES2295068T3 (es) *	1999-11-24	2008-04-16	MERCK & CO., INC.	Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.

1998
- 1998-07-18 GB GBGB9815567.4A patent/GB9815567D0/en not_active Ceased
1999
- 1999-07-14 AR ARP990103446A patent/AR019388A1/es not_active Application Discontinuation
- 1999-07-14 DZ DZ990145A patent/DZ2845A1/xx active
- 1999-07-14 GC GCP1999203 patent/GC0000105A/xx active
- 1999-07-15 ES ES99934698T patent/ES2189450T3/es not_active Expired - Lifetime
- 1999-07-15 WO PCT/EP1999/004991 patent/WO2000004033A1/en active IP Right Grant
- 1999-07-15 GE GEAP19995716A patent/GEP20033030B/en unknown
- 1999-07-15 TR TR2001/00111T patent/TR200100111T2/xx unknown
- 1999-07-15 SV SV1999000096A patent/SV1999000096A/es not_active Application Discontinuation
- 1999-07-15 EP EP99934698A patent/EP1098898B1/de not_active Expired - Lifetime
- 1999-07-15 PE PE1999000714A patent/PE20000869A1/es not_active Application Discontinuation
- 1999-07-15 HU HU0103432A patent/HU229700B1/hu unknown
- 1999-07-15 YU YU3401A patent/YU3401A/sh unknown
- 1999-07-15 GT GT199900111A patent/GT199900111A/es unknown
- 1999-07-15 AU AU50379/99A patent/AU766056B2/en not_active Expired
- 1999-07-15 CZ CZ20010219A patent/CZ300447B6/cs not_active IP Right Cessation
- 1999-07-15 OA OA1200100016A patent/OA11706A/fr unknown
- 1999-07-15 DE DE69904600T patent/DE69904600T2/de not_active Expired - Lifetime
- 1999-07-15 KR KR1020017000740A patent/KR100694721B1/ko not_active IP Right Cessation
- 1999-07-15 CO CO99044882A patent/CO5090836A1/es unknown
- 1999-07-15 EE EEP200100038A patent/EE200100038A/xx unknown
- 1999-07-15 JO JO19992114A patent/JO2114B1/en active
- 1999-07-15 SK SK76-2001A patent/SK285311B6/sk not_active IP Right Cessation
- 1999-07-15 CN CNB998108383A patent/CN1188422C/zh not_active Expired - Lifetime
- 1999-07-15 NZ NZ509291A patent/NZ509291A/en not_active IP Right Cessation
- 1999-07-15 DK DK99934698T patent/DK1098898T3/da active
- 1999-07-15 EP EP02013136A patent/EP1240903A3/de not_active Withdrawn
- 1999-07-15 EA EA200100053A patent/EA003191B1/ru not_active IP Right Cessation
- 1999-07-15 CA CA2337857A patent/CA2337857C/en not_active Expired - Lifetime
- 1999-07-15 JP JP2000560139A patent/JP3437553B2/ja not_active Expired - Lifetime
- 1999-07-15 MA MA25684A patent/MA26660A1/fr unknown
- 1999-07-15 ID IDW20010145A patent/ID28070A/id unknown
- 1999-07-15 PT PT99934698T patent/PT1098898E/pt unknown
- 1999-07-15 IL IL14082499A patent/IL140824A/en not_active IP Right Cessation
- 1999-07-15 PL PL99345620A patent/PL195736B1/pl unknown
- 1999-07-15 TN TNTNSN99145A patent/TNSN99145A1/fr unknown
- 1999-07-15 AP APAP/P/2001/002039A patent/AP2001002039A0/en unknown
- 1999-07-15 BR BRPI9912156A patent/BRPI9912156B8/pt not_active IP Right Cessation
- 1999-07-15 MY MYPI99002983A patent/MY122323A/en unknown
- 1999-07-15 US US09/744,051 patent/US6514953B1/en not_active Expired - Lifetime
- 1999-07-15 AT AT99934698T patent/ATE229964T1/de active
- 1999-07-16 PA PA19998477801A patent/PA8477801A1/es unknown
- 1999-08-06 TW TW088113428A patent/TWI245770B/zh not_active IP Right Cessation
2001
- 2001-01-12 IS IS5808A patent/IS5808A/is unknown
- 2001-01-15 ZA ZA200100417A patent/ZA200100417B/en unknown
- 2001-01-17 NO NO20010282A patent/NO329676B1/no not_active IP Right Cessation
- 2001-01-17 HR HR20010046A patent/HRP20010046A2/hr not_active Application Discontinuation
- 2001-02-14 BG BG105253A patent/BG105253A/xx unknown
- 2001-07-13 HK HK01104903A patent/HK1034261A1/xx not_active IP Right Cessation
2002
- 2002-11-25 US US10/303,366 patent/US20030096795A1/en not_active Abandoned
- 2002-11-25 US US10/303,213 patent/US20030100537A1/en not_active Abandoned

Also Published As

Publication number	Publication date
GEP20033030B (en)	2003-07-25
DE69904600T2 (de)	2003-11-13
GC0000105A (en)	2005-06-29
SK762001A3 (en)	2001-10-08
EP1240903A2 (de)	2002-09-18
GT199900111A (es)	2001-01-05
ID28070A (id)	2001-05-03
AR019388A1 (es)	2002-02-13
TNSN99145A1 (fr)	2005-11-10
GB9815567D0 (en)	1998-09-16
NO20010282D0 (no)	2001-01-17
NZ509291A (en)	2003-05-30
YU3401A (sh)	2005-06-10
SK285311B6 (sk)	2006-10-05
JP3437553B2 (ja)	2003-08-18
EP1098898B1 (de)	2002-12-18
BRPI9912156B1 (pt)	2016-07-26
ZA200100417B (en)	2002-02-27
IL140824A (en)	2004-09-27
US20030100537A1 (en)	2003-05-29
DZ2845A1 (fr)	2003-12-01
NO329676B1 (no)	2010-11-29
EP1098898A1 (de)	2001-05-16
US6514953B1 (en)	2003-02-04
JO2114B1 (en)	2000-05-21
HU229700B1 (en)	2014-05-28
MY122323A (en)	2006-04-29
PL345620A1 (en)	2002-01-02
EA003191B1 (ru)	2003-02-27
EA200100053A1 (ru)	2001-08-27
CN1324363A (zh)	2001-11-28
HK1034261A1 (en)	2001-10-19
CO5090836A1 (es)	2001-10-30
KR100694721B1 (ko)	2007-03-15
ES2189450T3 (es)	2003-07-01
IL140824A0 (en)	2002-02-10
EE200100038A (et)	2002-06-17
AP2001002039A0 (en)	2001-03-31
PL195736B1 (pl)	2007-10-31
EP1240903A3 (de)	2003-02-12
ATE229964T1 (de)	2003-01-15
NO20010282L (no)	2001-03-07
AU766056B2 (en)	2003-10-09
MA26660A1 (fr)	2004-12-20
US20030096795A1 (en)	2003-05-22
BR9912156A (pt)	2001-04-10
DE69904600D1 (de)	2003-01-30
PT1098898E (pt)	2003-04-30
HUP0103432A3 (en)	2003-01-28
CA2337857A1 (en)	2000-01-27
WO2000004033A1 (en)	2000-01-27
CZ300447B6 (cs)	2009-05-20
IS5808A (is)	2001-01-12
SV1999000096A (es)	2000-07-06
CN1188422C (zh)	2005-02-09
CZ2001219A3 (cs)	2001-07-11
AU5037999A (en)	2000-02-07
PA8477801A1 (es)	2000-05-24
HUP0103432A2 (hu)	2002-04-29
OA11706A (en)	2005-01-13
DK1098898T3 (da)	2003-04-07
JP2003521447A (ja)	2003-07-15
CA2337857C (en)	2011-01-25
PE20000869A1 (es)	2000-09-08
KR20010071952A (ko)	2001-07-31
TR200100111T2 (tr)	2002-02-21
TWI245770B (en)	2005-12-21
HRP20010046A2 (en)	2002-02-28
BRPI9912156B8 (pt)	2021-05-25

Publication	Publication Date	Title
BG105253A (en)	2001-12-29	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
AU5812400A (en)	2001-01-02	Carrier-drug conjugate
MY125821A (en)	2006-08-30	Pharmaceutical composition of topiramate
MX9707535A (es)	1998-07-31	Uso de derivados de vitamina d2 o de vitamina d4 en la preparacion de un farmaco para el tratamiento de hiperparatiroidismo secundario.
EP1632248B8 (de)	2010-12-29	Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
MY120683A (en)	2005-11-30	New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
WO2001000635A3 (en)	2003-04-17	Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
AU1945495A (en)	1995-10-03	Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
MX9604762A (es)	1997-04-30	Nuevas sulfonamidas y procedimiento para su preparacion.
ZA966953B (en)	1998-02-16	Pharmaceutical composition.
EP1607399A3 (de)	2006-01-04	Bis-(N,N'-bis-(2-haloethyl)amino)-phosphoramidate als anti-Tumormittel
TH69155A3 (th)	2005-06-14	แคลเซียม (3s) เททระไฮโดร-3-ฟิวแรนิล (1s,2r)-3-[[(4-อะมิโนฟีนิล)ซัลโฟนิล](ไอโซบิวทิล)อะมิโน]-1-เบนซิล-2-(ฟอสโฟโนออกซี)โพรพิลคาร์บาเมต
BG104829A (en)	2001-05-31	Crystalline forms of 1s-[1alpha (2s,3r), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl-9[[(1-isoquinolyl)carbonyl]-a mino]octahydro-6h-pyridazino[1,2-a][1,2]diazepin-1-carboxamide
TH56922C3 (th)	2017-08-23	แคลเซียม (3s) เททระไฮโดร-3-ฟิวแรนิล (1s,2r)-3-[[(4-อะมิโนฟีนิล)ซัลโฟนิล](ไอโซบิวทิล)อะมิโน]-1-เบนซิล-2-(ฟอสโฟโนออกซี)โพรพิลคาร์บาเมต
SI1098898T1 (en)	2003-08-31	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
TW200501942A (en)	2005-01-16	Pharmaceutical compositions
NZ323964A (en)	2000-01-28	4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1-hydroxy-9-oxo-19-nor-cy clopropa[g]tax-11-ene-13alpha-yl
MX9802268A (es)	1998-08-30	Nuevos derivados de la substancia pf1022 de ciclodepsipeptido.
MX9709684A (es)	1998-06-28	Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
MX9606264A (es)	1997-10-31	Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.